Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3753680 | 0.88 | HTT (0.46) | TSHRNPSR1OPRM1F2SLC6A2 | |
| SCHEMBL24113114 | 0.83 | TSHR (0.44) | TSHRNPSR1OPRM1F2SLC6A2 | |
| SCHEMBL18103323 | 0.82 | MAPK1 (0.36) | TSHRNPSR1F2SLC6A2SLC6A4 | |
| SCHEMBL4156187 | 0.81 | RORC (0.40) | TSHRNPSR1OPRM1OPRK1F2 | |
| SCHEMBL1426173 | 0.81 | LMNA (0.46) | TSHRNPSR1F2SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL15569689 | 0.80 | MEN1 (0.57) | TSHRNPSR1 | |
| SCHEMBL4146467 | 0.79 | MEN1 (0.39) | TSHRNPSR1OPRM1F2SLC6A2 | |
| SCHEMBL4707323 | 0.79 | TSHR (0.41) | TSHRNPSR1OPRM1OPRK1F2 | |
| SCHEMBL7529705 | 0.77 | TSHR (0.47) | TSHRNPSR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29596350 | 0.77 | TSHR (0.47) | TSHRNPSR1F2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879863-A1 | AMIDE RESORCINOL COMPOUNDS | Pfizer, Inc. (US) | 2008-01-23 | — | — | EP | claimed |
| WO-2006117669-A1 | AMIDE RESORCINOL COMPOUNDS | PFIZER INC. (US) | 2006-11-09 | — | — | WO | claimed |
| US-20090215742-A1 | AMIDE RESORCINOL COMPOUNDS | PFIZER, INC. | 2009-08-27 | — | — | US | disclosed |
| EP-1879863-A1 | AMIDE RESORCINOL COMPOUNDS | Pfizer, Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006117669-A1 | AMIDE RESORCINOL COMPOUNDS | PFIZER INC. (US) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215742-A1 | AMIDE RESORCINOL COMPOUNDS | HSP90AB1, HSP90AA1, HSP90AB2P | TSHR 3980/4885NPSR1 659/4885OPRM1 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.